Welcome to our dedicated page for Drugs Made In Amer Acqutn SEC filings (Ticker: DMAAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Drugs Made In Amer Acqutn's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Drugs Made In Amer Acqutn's regulatory disclosures and financial reporting.
Drugs Made In America Acquisition Corp. entered into a financing arrangement with BV Advisory Partners, LLC, starting with a $100,000 interim convertible note as the first tranche of a contemplated $500,000 funding commitment. The note matures in six months, bears no interest, and can convert, at the investor’s option after a business combination, into shares of the combined entity at a 35% discount to the market price at conversion.
The company plans to use the proceeds for accounting, audit, and other business combination-related expenses and has not yet agreed to a merger. Under the related investment agreement, a second tranche of $200,000 is expected within 21 days, with remaining amounts available on an as-needed basis. The investor is also being offered at least 40% of the economic benefit equivalent to sponsor-level economics and has introduced a potential business combination target focused on artificial intelligence, machine learning, quantum analytics, and cybersecurity solutions, though no letter of intent or definitive agreement has been signed.
Drugs Made In America Acquisition Corp. reported leadership changes following issues at an affiliated SPAC’s working capital account. The sponsor of Drugs Made In America Acquisition II Corp. withdrew an aggregate $1,100,000 from the affiliate’s working capital account, including $325,000 to repay a working capital note and $208,000 for other offering costs and expenses. The affiliate’s financial statements also showed a $566,269 overpayment to the sponsor, and the sponsor later withdrew no less than $200,000 more to pay expenses unrelated to the affiliate. After the affiliate’s board directed the sponsor to return the full overpayment amount and learned on February 12, 2026 that it could not be repaid, the boards of the affiliate and the company requested the resignation of Lynn Stockwell as Chief Executive Officer, Executive Chair, and director. The board received her resignation effective February 28, 2026 and removed her from all roles. On the same date, Roger Bendelac was appointed Chief Executive Officer of the company; his compensation will be determined later.